The page below is a sample from the LabCE course Ebola Virus Disease (EVD) and Clinical Laboratory Safety in the United States. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Ebola Virus Disease (EVD) and Clinical Laboratory Safety in the United States (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 97 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Additional Testing Options for Consideration

The Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on October 25, 2014 for the FilmArray Biothreat-E (BioFire Diagnostics), used for the presumptive identification of Ebola virus (Zaire). This provides laboratories, certified under CLIA to perform moderate to high complexity testing, with a rapid option (approximately one hour) to conduct a presumptive, in-house Ebola test for use with patients showing signs and symptoms of EVD.
All EVD suspect specimens must still be sent to the CDC or other Laboratory Response Network (LRN) facility. However, the implementation of in-house, rapid, presumptive Ebola testing can have a big impact on the facility's ability to provide additional diagnostic testing needed for the care of the patient. Each laboratory, working in a coordinated effort with their facility administrators and clinicians, should carefully consider and evaluate options that provide the best testing approach for their patients.

Additional information regarding BioFire's FilmArray Biothreat-E is available at: http://biofiredefense.com/biosurveillance-systems/biothreat-e